These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21086021)

  • 21. Cost effectiveness of anticoagulation in acute coronary syndromes.
    Latour-Pérez J; de-Miguel-Balsa E
    Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
    Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
    Heer T; Juenger C; Gitt AK; Bauer T; Towae F; Zahn R; Senges J; Zeymer U;
    J Thromb Thrombolysis; 2009 Oct; 28(3):325-32. PubMed ID: 19101783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
    Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
    Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
    Li Y; Rodriquez M; Spencer FA; Becker RC
    J Thromb Thrombolysis; 2002 Oct; 14(2):123-9. PubMed ID: 12714831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Factor Xa Activity of Fixed-Dose Fondaparinux in Low-Body-Weight Patients With Acute Coronary Syndrome.
    Wongcharoen W; Tantisirivit N; Norasetthada L; Gunaparn S; Phrommintikul A
    Ann Pharmacother; 2020 Nov; 54(11):1083-1089. PubMed ID: 32462894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets.
    Stevic I; Chan HH; Chander A; Berry LR; Chan AK
    Thromb Haemost; 2013 Jun; 109(6):1016-24. PubMed ID: 23494009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.
    Lev EI; Hasdai D; Scapa E; Tobar A; Assali A; Lahav J; Battler A; Badimon JJ; Kornowski R
    J Am Coll Cardiol; 2004 Mar; 43(6):966-71. PubMed ID: 15028351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin.
    Maurice-Dror C; Litvak M; Keren-Politansky A; Ackerman S; Haim N; Nadir Y
    J Thromb Thrombolysis; 2020 Jul; 50(1):112-122. PubMed ID: 32377957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L; Bal dit Sollier C; Martin J
    Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
    Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
    J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
    Shimbo D; Osende J; Chen J; Robbins J; Shimoto Y; Kunitada S; Fuster V; Badimon JJ
    Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.
    Hakki SI; Fareed J; Hoppensteadt DA; Abdullah H; Camblin J; Nasseri AF; Hamadeh O; Wright T
    Clin Appl Thromb Hemost; 2001 Jan; 7(1):65-71. PubMed ID: 11190908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
    Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
    Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
    Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
    Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factor Xa inhibitors for acute coronary syndromes.
    Brito V; Ciapponi A; Kwong J
    Cochrane Database Syst Rev; 2011 Jan; (1):CD007038. PubMed ID: 21249686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.